Do analysts rate OPXS or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optex Systems 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, OPXS or QUCY?

Optex Systems has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Optex Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Optex Systems $41.18M 1.96 $5.15M $0.59 19.68 Mainz Biomed $540K 37.19 -$16.21M -$47.60 N/A

Do analysts recommend QUCY or MOB?

Mobilicom has a consensus price target of $2,750.00, suggesting a potential upside of 46,989.04%. Given Mobilicom's higher probable upside, analysts plainly believe Mobilicom is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Mobilicom 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings and valuation, QUCY or MOB?

Mainz Biomed has higher earnings, but lower revenue than Mobilicom. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $540K 37.19 -$16.21M -$47.60 N/A Mobilicom $3.36M 21.22 -$23.73M N/A N/A

Is QUCY or MOB more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Mobilicom N/A N/A N/A

Do analysts recommend QUCY or XTIA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 XTI Aerospace 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate TPCS or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Techprecision 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts rate QUCY or SYPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Sypris Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Mainz Biomed (QUCY) Competitors

$1.37 -0.02 (-1.44%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.02 (+1.82%)

As of 06:53 AM Eastern

Compare

QUCY vs. OPXS, MOB, XTIA, TPCS, and SYPR

Should you buy Mainz Biomed stock or one of its competitors? Mainz Biomed's main competitors and comparable companies include Optex Systems (OPXS), Mobilicom (MOB), XTI Aerospace (XTIA), Techprecision (TPCS), and Sypris Solutions (SYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "aerospace & defense" industry.

How does Mainz Biomed compare to Optex Systems?

Optex Systems (NASDAQ:OPXS) and Mainz Biomed (NASDAQ:QUCY) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optex Systems	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	3.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Mainz Biomed had 11 more articles in the media than Optex Systems. MarketBeat recorded 14 mentions for Mainz Biomed and 3 mentions for Optex Systems. Mainz Biomed's average media sentiment score of 1.94 beat Optex Systems' score of 1.15 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Optex Systems	Positive
Mainz Biomed	Very Positive

Optex Systems has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Optex Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optex Systems	$41.18M	1.96	$5.15M	$0.59	19.68
Mainz Biomed	$540K	37.19	-$16.21M	-$47.60	N/A

Optex Systems has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

Optex Systems has a net margin of 10.00% compared to Mainz Biomed's net margin of 0.00%. Optex Systems' return on equity of 19.33% beat Mainz Biomed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optex Systems	10.00%	19.33%	15.82%
Mainz Biomed	N/A	N/A	N/A

19.1% of Optex Systems shares are owned by institutional investors. 27.7% of Optex Systems shares are owned by insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Optex Systems beats Mainz Biomed on 10 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Mobilicom?

Mainz Biomed (NASDAQ:QUCY) and Mobilicom (NASDAQ:MOB) are both small-cap industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Mobilicom	N/A	N/A	N/A

Mainz Biomed has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Mobilicom has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Mobilicom has a consensus price target of $2,750.00, suggesting a potential upside of 46,989.04%. Given Mobilicom's higher probable upside, analysts plainly believe Mobilicom is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Mobilicom	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mainz Biomed has higher earnings, but lower revenue than Mobilicom.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$540K	37.19	-$16.21M	-$47.60	N/A
Mobilicom	$3.36M	21.22	-$23.73M	N/A	N/A

In the previous week, Mainz Biomed had 11 more articles in the media than Mobilicom. MarketBeat recorded 14 mentions for Mainz Biomed and 3 mentions for Mobilicom. Mainz Biomed's average media sentiment score of 1.94 beat Mobilicom's score of 0.36 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Very Positive
Mobilicom	Neutral

13.6% of Mobilicom shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by insiders. Comparatively, 7.2% of Mobilicom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Mainz Biomed beats Mobilicom on 7 of the 12 factors compared between the two stocks.

How does Mainz Biomed compare to XTI Aerospace?

Mainz Biomed (NASDAQ:QUCY) and XTI Aerospace (NASDAQ:XTIA) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Mainz Biomed had 9 more articles in the media than XTI Aerospace. MarketBeat recorded 14 mentions for Mainz Biomed and 5 mentions for XTI Aerospace. Mainz Biomed's average media sentiment score of 1.94 beat XTI Aerospace's score of 0.37 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Very Positive
XTI Aerospace	Neutral

Mainz Biomed has higher earnings, but lower revenue than XTI Aerospace. XTI Aerospace is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$540K	37.19	-$16.21M	-$47.60	N/A
XTI Aerospace	$22.49M	2.72	-$68.76M	-$5.20	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XTI Aerospace	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mainz Biomed has a net margin of 0.00% compared to XTI Aerospace's net margin of -171.13%. Mainz Biomed's return on equity of 0.00% beat XTI Aerospace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
XTI Aerospace	-171.13%	-2,044.78%	-105.02%

11.7% of XTI Aerospace shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by company insiders. Comparatively, 7.4% of XTI Aerospace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mainz Biomed has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, XTI Aerospace has a beta of 4.79, meaning that its share price is 379% more volatile than the broader market.

Summary

Mainz Biomed beats XTI Aerospace on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Techprecision?

Techprecision (NASDAQ:TPCS) and Mainz Biomed (NASDAQ:QUCY) are both small-cap industrials companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Mainz Biomed has a net margin of 0.00% compared to Techprecision's net margin of -5.26%. Mainz Biomed's return on equity of 0.00% beat Techprecision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Techprecision	-5.26%	-20.19%	-5.08%
Mainz Biomed	N/A	N/A	N/A

Techprecision has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

15.5% of Techprecision shares are held by institutional investors. 15.3% of Techprecision shares are held by insiders. Comparatively, 3.1% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Mainz Biomed had 12 more articles in the media than Techprecision. MarketBeat recorded 14 mentions for Mainz Biomed and 2 mentions for Techprecision. Mainz Biomed's average media sentiment score of 1.94 beat Techprecision's score of 0.63 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Techprecision	Positive
Mainz Biomed	Very Positive

Techprecision has higher revenue and earnings than Mainz Biomed. Techprecision is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Techprecision	$31.64M	1.54	-$1.66M	-$0.17	N/A
Mainz Biomed	$540K	37.19	-$16.21M	-$47.60	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Techprecision	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Mainz Biomed beats Techprecision on 10 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Sypris Solutions?

Mainz Biomed (NASDAQ:QUCY) and Sypris Solutions (NASDAQ:SYPR) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Sypris Solutions has higher revenue and earnings than Mainz Biomed. Sypris Solutions is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$540K	37.19	-$16.21M	-$47.60	N/A
Sypris Solutions	$116.19M	0.41	-$6.34M	-$0.42	N/A

In the previous week, Mainz Biomed had 11 more articles in the media than Sypris Solutions. MarketBeat recorded 14 mentions for Mainz Biomed and 3 mentions for Sypris Solutions. Mainz Biomed's average media sentiment score of 1.94 beat Sypris Solutions' score of 0.44 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Very Positive
Sypris Solutions	Neutral

Mainz Biomed has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Sypris Solutions has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

44.7% of Sypris Solutions shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by insiders. Comparatively, 47.9% of Sypris Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mainz Biomed has a net margin of 0.00% compared to Sypris Solutions' net margin of -8.23%. Mainz Biomed's return on equity of 0.00% beat Sypris Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Sypris Solutions	-8.23%	-54.45%	-8.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Sypris Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mainz Biomed beats Sypris Solutions on 10 of the 15 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QUCY vs. The Competition

Export

Metric	Mainz Biomed	Aerospace & Defense Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$20.38M	$23.42B	$10.83B	$12.96B
Dividend Yield	N/A	1.60%	97.10%	10.34%
P/E Ratio	-0.03	45.48	28.13	25.05
Price / Sales	37.19	167.65	354.68	69.51
Price / Cash	N/A	29.79	24.70	50.42
Price / Book	19.57	8.64	4.53	6.18
Net Income	-$16.21M	$562.35M	$607.12M	$347.05M
7 Day Performance	-5.52%	2.65%	1.38%	1.24%
1 Month Performance	0.74%	6.99%	2.41%	-0.65%
1 Year Performance	N/A	22.81%	13.67%	20.12%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QUCY Mainz Biomed	0.5946 of 5 stars	$1.37 -1.4%	N/A	N/A	$20.38M	$540K	N/A	30	Positive News Analyst Upgrade Analyst Revision Gap Up
OPXS Optex Systems	1.5979 of 5 stars	$11.99 -0.6%	N/A	-9.6%	$83.45M	$41.34M	20.32	80	News Coverage Earnings Report Gap Up
MOB Mobilicom	2.5335 of 5 stars	$5.91 +2.2%	$2,750.00 +46,431.3%	-99.5%	$72.19M	$3.36M	N/A	24	Upcoming Earnings
XTIA XTI Aerospace	0.8879 of 5 stars	$1.53 +2.0%	N/A	-10.7%	$58.87M	$22.49M	N/A	12	News Coverage
TPCS Techprecision	0.5096 of 5 stars	$4.96 +6.9%	N/A	-14.6%	$49.72M	$31.64M	N/A	160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QUCY) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (QUCY) Competitors

QUCY vs. OPXS, MOB, XTIA, TPCS, and SYPR

How does Mainz Biomed compare to Optex Systems?

Summary

How does Mainz Biomed compare to Mobilicom?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Summary

How does Mainz Biomed compare to Techprecision?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (QUCY) Competitors

QUCY vs. OPXS, MOB, XTIA, TPCS, and SYPR

How does Mainz Biomed compare to Optex Systems?

Do analysts rate OPXS or QUCY?

Does the media favor OPXS or QUCY?

Which has stronger earnings & valuation, OPXS or QUCY?

Which has more volatility and risk, OPXS or QUCY?

Is OPXS or QUCY more profitable?

Do institutionals & insiders have more ownership in OPXS or QUCY?

Summary

How does Mainz Biomed compare to Mobilicom?

Is QUCY or MOB more profitable?

Which has more risk & volatility, QUCY or MOB?

Do analysts recommend QUCY or MOB?

Which has preferable earnings and valuation, QUCY or MOB?

Does the media prefer QUCY or MOB?

Do insiders & institutionals hold more shares of QUCY or MOB?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Does the media prefer QUCY or XTIA?

Which has stronger earnings and valuation, QUCY or XTIA?

Do analysts recommend QUCY or XTIA?

Is QUCY or XTIA more profitable?

Do institutionals & insiders believe in QUCY or XTIA?

Which has more risk and volatility, QUCY or XTIA?

Summary

How does Mainz Biomed compare to Techprecision?

Is TPCS or QUCY more profitable?

Which has more risk and volatility, TPCS or QUCY?

Do institutionals and insiders hold more shares of TPCS or QUCY?

Does the media favor TPCS or QUCY?

Which has preferable earnings & valuation, TPCS or QUCY?

Do analysts rate TPCS or QUCY?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Which has higher earnings & valuation, QUCY or SYPR?

Does the media prefer QUCY or SYPR?

Which has more risk & volatility, QUCY or SYPR?

Do institutionals & insiders hold more shares of QUCY or SYPR?

Is QUCY or SYPR more profitable?

Do analysts rate QUCY or SYPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools